Payment overview · 2025
General Payments
$316.79
16 reported records · 11 companies
Healthcare provider profile · identity verified
Jay Mccutcheon Jones, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · DALLAS, TX · NPI 1740235308
Verified facts
What the public records show
CMS Open Payments records show Jay Mccutcheon Jones, M.D. received $316.79 in general payments during 2025 across 16 reported records.
Abbott Laboratories accounted for 22.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Shingrix, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Shingrix by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $70.56 | 22.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $68.97 | 21.8% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $29.25 | 9.2% | 2 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $23.70 | 7.5% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $23.44 | 7.4% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $19.79 | 6.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.69 | 6.2% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$16.04 | 5.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.92 | 5.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.21 | 4.8% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $14.22 | 4.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $316.79 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $68.97 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $68.97 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $68.97 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $49.18 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $29.25 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $29.25 | 2 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $23.70 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $23.44 | 1 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $21.38 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $19.69 | 1 | 2025 |
Source payment records
|
|||||
| O-ARM Normalized: o arm |
Device | Medtronic, Inc. | $16.04 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $15.92 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.92 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $14.22 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $13.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 78 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
78 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
61 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
24 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 901 | 252 |
| Losartan Potassium | Losartan Potassium | 500 | 132 |
| Amlodipine Besylate | Amlodipine Besylate | 372 | 105 |
| Levothyroxine Sodium | Levothyroxine Sodium | 338 | 92 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 247 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 221 | 66 |
| Trazodone Hcl | Trazodone Hcl | 178 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 172 | 58 |
| Pravastatin Sodium | Pravastatin Sodium | 157 | 46 |
| Metformin Hcl Er | Metformin Hcl | 145 | 44 |
| Omeprazole | Omeprazole | 145 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 145 | 48 |
| Ezetimibe | Ezetimibe | 114 | 34 |
| Ibandronate Sodium | Ibandronate Sodium | 104 | 27 |
| Montelukast Sodium | Montelukast Sodium | 102 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 101 | 25 |
| Finasteride | Finasteride | 101 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 100 | 30 |
| Gabapentin | Gabapentin | 97 | 31 |
| Celecoxib | Celecoxib | 91 | 32 |
| Ozempic | Semaglutide | 83 | 14 |
| Synthroid | Levothyroxine Sodium | 78 | 19 |
| Lisinopril | Lisinopril | 74 | 25 |
| Mounjaro | Tirzepatide | 74 | 11 |
| Donepezil Hcl | Donepezil Hcl | 73 | 20 |
| Memantine Hcl | Memantine Hcl | 73 | 16 |
| Allopurinol | Allopurinol | 65 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 62 | 18 |
| Eliquis | Apixaban | 61 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 57 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 52 | 23 |
| Simvastatin | Simvastatin | 51 | 15 |
| Furosemide | Furosemide | 49 | 16 |
| Ramipril | Ramipril | 49 | 15 |
| Carvedilol | Carvedilol | 48 | 13 |
| Potassium Chloride | Potassium Chloride | 47 | 13 |
| Januvia | Sitagliptin Phosphate | 45 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 42 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 41 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 38 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 35 | 13 |
| Valsartan | Valsartan | 34 | 11 |
| Prednisone | Prednisone | 31 | 19 |
| Meloxicam | Meloxicam | 30 | 12 |
| Sertraline Hcl | Sertraline Hcl | 30 | suppressed |
| Baclofen | Baclofen | 29 | 16 |
| Doxepin Hcl | Doxepin Hcl | 29 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 26 |
| Pregabalin | Pregabalin | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 25 | 11 |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 24 |
| Metformin Hcl | Metformin Hcl | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Famotidine | Famotidine | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Unithroid | Levothyroxine Sodium | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Alprazolam | Alprazolam | 20 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 14 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 13 |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Famciclovir | Famciclovir | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $316.79 · 16 records | Abbott Laboratories | ABRYSVO, AREXVY, BEXSERO, COMIRNATY, ESPRIT, FREESTYLE LIBRE 3, GEMTESA, O-ARM, OTEZLA, PREVNAR 20, REPATHA, REXULTI, REZDIFFRA, SHINGRIX, SYNTHROID, UBRELVY, XYOSTED | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Shingrix play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error